Study Shows Vonoprazan-Based Regimens Noninferior to PPI-Based Triple Therapy
Vonoprazan is an oral small molecule potassium-competitive acid blocker.
Hyperacidity/GERD/Ulcers
Proton Pump Inhibitor Use Linked to Asthma Risk in Children
Findings showed that children who were initiated on PPIs were 57% more likely to be diagnosed with asthma.
OTC Medicines Containing “Clean” Inactive Ingredients Launched
Genexa has launched 4 over-the-counter (OTC) medicines that contain no artificial ingredients.
Proton Pump Inhibitor Use Linked to Increased Diabetes Risk
Type 2 diabetes risk increased with increasing length of PPI use, particularly use for more than two years.
Clinical Program for Investigational GERD Drug Discontinued
The bile acid sequestrant was designed to be maintained in the stomach over an extended period of time where it was expected to intercept bile before it reached the esophagus.
Coffee, Tea, Soda Tied to Higher Risk for Gastroesophageal Reflux
Consuming water, juice, milk not linked to increased risk for gastroesophageal reflux symptoms
Risk for COVID-19 Increased for Adults Taking PPIs
Dose-response relationship observed; risk up 3.67-fold for those using PPIs up to twice daily.
Amneal’s Nizatidine Oral Solution Recalled Due to NDMA Concerns
The Food and Drug Administration (FDA) is alerting healthcare professionals and consumers of a voluntary recall of 3 lots of Amneal’s Nizatidine Oral Solution (15mg/mL) due to potential contamination with N-Nitrosodimethylamine (NDMA), a probable human carcinogen.
Suppressing Stomach Acid May Up Intestinal Growth of MDROs
Gastric acid suppression increased odds of intestinal colonization with MDROs by about 75%.
MPR Weekly Dose Podcast Episode 28
This episode covers the latest COVID-19 news including drug shortages, a new point-of-care diagnostic tool, the role of vitamin C, misuse of non-pharmacological chloroquine, and also some big news about a popular heartburn drug.
